Tykhe Corp
Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
Tykhe Corp (HALB) - Net Assets
Latest net assets as of October 2025: $-849.72K USD
Based on the latest financial reports, Tykhe Corp (HALB) has net assets worth $-849.72K USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.30K) and total liabilities ($854.03K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-849.72K |
| % of Total Assets | -19747.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tykhe Corp - Net Assets Trend (2008–2025)
This chart illustrates how Tykhe Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tykhe Corp (2008–2025)
The table below shows the annual net assets of Tykhe Corp from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | $-913.11K | -27.07% |
| 2024-07-31 | $-718.59K | +22.43% |
| 2023-07-31 | $-926.37K | -27.26% |
| 2022-07-31 | $-727.91K | -49.97% |
| 2021-07-31 | $-485.36K | -70.31% |
| 2020-07-31 | $-284.98K | +54.22% |
| 2017-07-31 | $-622.45K | +1.06% |
| 2016-07-31 | $-629.09K | -46.48% |
| 2011-07-31 | $-429.48K | +51.16% |
| 2010-07-31 | $-879.27K | -42.91% |
| 2009-07-31 | $-615.24K | -1604.50% |
| 2008-07-31 | $-36.09K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tykhe Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 696251800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $63.59K | % |
| Other Components | $6.02 Million | % |
| Total Equity | $-913.11K | 100.00% |
Tykhe Corp Competitors by Market Cap
The table below lists competitors of Tykhe Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kings Arms Yard Vct Plc
LSE:KAY
|
$20.84 |
|
Topcon Corporation
PINK:TOPCF
|
$21.00 |
|
Naeem Holding
EGX:NAHO
|
$21.13 |
|
Paragon Shipping Inc
PINK:PRGNF
|
$21.34 |
|
Australian Oil & Gas Corporation
PINK:AOGC
|
$20.80 |
|
GAS2GRID
BE:GT4
|
$20.74 |
|
Buyer Group International Inc
PINK:BYRG
|
$20.50 |
|
ASO SAVINGS AND LOANS PLC
XNSA:ASOSAVINGS
|
$20.43 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tykhe Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -718,588 to -913,113, a change of -194,525.
- Net loss of 20,071 reduced equity.
- Other factors decreased equity by 174,454.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.07K | -2.2% |
| Other Changes | $-174.45K | -19.11% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Tykhe Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-07-31 | $0.00 | $0.00 | x |
| 2009-07-31 | $-0.03 | $0.00 | x |
| 2010-07-31 | $-0.03 | $0.00 | x |
| 2011-07-31 | $-0.02 | $0.00 | x |
| 2016-07-31 | $0.00 | $0.00 | x |
| 2017-07-31 | $0.00 | $0.00 | x |
| 2019-07-31 | $0.00 | $0.00 | x |
| 2020-07-31 | $0.00 | $0.00 | x |
| 2021-07-31 | $0.00 | $0.00 | x |
| 2022-07-31 | $0.00 | $0.00 | x |
| 2023-07-31 | $0.00 | $0.00 | x |
| 2024-07-31 | $0.00 | $0.00 | x |
| 2025-07-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tykhe Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | -514.54% | 0.02x | 0.00x | $-32.49K |
| 2009 | 0.00% | -15262.16% | 0.08x | 0.00x | $-1.15 Million |
| 2010 | 0.00% | -970.03% | 0.33x | 0.00x | $-236.07K |
| 2011 | 0.00% | 225.80% | 0.68x | 0.00x | $223.76K |
| 2016 | 0.00% | 3.64% | 0.27x | 0.00x | $68.89K |
| 2017 | 0.00% | -246.65% | 0.36x | 0.00x | $-310.75K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $25.08K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2021 | 0.00% | -16447.82% | 0.08x | 0.00x | $-813.00K |
| 2022 | 0.00% | -20258.65% | 0.47x | 0.00x | $-1.55 Million |
| 2023 | 0.00% | -16663.19% | 0.22x | 0.00x | $-361.44K |
| 2024 | 0.00% | -7975.58% | 0.10x | 0.00x | $-7.82K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $71.24K |
Industry Comparison
This section compares Tykhe Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tykhe Corp (HALB) | $-849.72K | 0.00% | N/A | $20.80 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |